CA2446093A1 - Methods of preventing uvb-induced skin damage - Google Patents

Methods of preventing uvb-induced skin damage Download PDF

Info

Publication number
CA2446093A1
CA2446093A1 CA002446093A CA2446093A CA2446093A1 CA 2446093 A1 CA2446093 A1 CA 2446093A1 CA 002446093 A CA002446093 A CA 002446093A CA 2446093 A CA2446093 A CA 2446093A CA 2446093 A1 CA2446093 A1 CA 2446093A1
Authority
CA
Canada
Prior art keywords
tsp
angiogenesis
subject
composition
uvb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002446093A
Other languages
English (en)
French (fr)
Inventor
Michael J. Detmar
Kiichiro Yano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2446093A1 publication Critical patent/CA2446093A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002446093A 2001-04-13 2002-04-11 Methods of preventing uvb-induced skin damage Abandoned CA2446093A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28387401P 2001-04-13 2001-04-13
US60/283,874 2001-04-13
PCT/US2002/011403 WO2002083088A1 (en) 2001-04-13 2002-04-11 Methods of preventing uvb-induced skin damage

Publications (1)

Publication Number Publication Date
CA2446093A1 true CA2446093A1 (en) 2002-10-24

Family

ID=23087934

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002446093A Abandoned CA2446093A1 (en) 2001-04-13 2002-04-11 Methods of preventing uvb-induced skin damage

Country Status (8)

Country Link
US (1) US6712617B2 (enExample)
EP (1) EP1377253A4 (enExample)
JP (1) JP2004526758A (enExample)
KR (2) KR20080108366A (enExample)
CN (1) CN100340287C (enExample)
CA (1) CA2446093A1 (enExample)
TW (1) TWI233361B (enExample)
WO (1) WO2002083088A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) * 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
US7238370B2 (en) * 2002-06-14 2007-07-03 Rosenberg E William Method and composition to prevent and treat photoaging of skin
CN100574743C (zh) * 2002-06-25 2009-12-30 株式会社资生堂 抗老化剂
RU2338741C2 (ru) * 2002-07-31 2008-11-20 Мершан Корпорейшн Новые физиологически активные вещества
US7576204B2 (en) * 2002-07-31 2009-08-18 Mercian Corporation Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same
WO2004032963A2 (en) 2002-10-04 2004-04-22 Photokinetix Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
DE10254214A1 (de) * 2002-11-20 2004-06-09 Beiersdorf Ag Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
RU2330069C2 (ru) * 2002-11-29 2008-07-27 Мершан Корпорейшн Способ получения макролидного соединения и штаммы streptomyces sp., mortierella sp. и micromonosporaceae
WO2005097187A2 (en) * 2004-04-01 2005-10-20 The General Hospital Corporation Methods of preventing uvb-induced skin damage
US20050276762A1 (en) * 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
WO2006042114A1 (en) * 2004-10-06 2006-04-20 Cook, Inc. Emboli capturing device having a coil and method for capturing emboli
CN101057438A (zh) 2004-10-12 2007-10-17 阿瓦雷公司 电信环境中的资源共享
BRPI0613548A2 (pt) * 2005-05-05 2011-01-18 Genencor Int composições de cuidado pessoal e métodos para seu uso
US20090220627A1 (en) * 2005-09-16 2009-09-03 Kiyotaka Hasegawa Novel vascular endothelial growth factor expression inhibitors
JP2009523807A (ja) 2006-01-18 2009-06-25 ザ ジェネラル ホスピタル コーポレイション リンパ機能を高める方法
JP2009533973A (ja) 2006-04-12 2009-09-17 アウェア， インコーポレイテッド パケット再送信ならびにメモリの共有
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
JPWO2008020584A1 (ja) * 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
US7790887B2 (en) * 2007-01-29 2010-09-07 Eisai R&D Management Co., Ltd. Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same
TW200918099A (en) 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
WO2011040496A1 (ja) 2009-09-30 2011-04-07 株式会社資生堂 ヘパラナーゼ活性阻害剤
WO2021133858A1 (en) * 2019-12-24 2021-07-01 Juvena Therapeutics, Inc. Heparin-associated polypeptides and uses thereof
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND USES THEREOF
EP4359425B1 (en) 2021-06-21 2026-08-05 Juvena Therapeutics, Inc. Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025334A (en) * 1994-04-28 2000-02-15 Les Laboratoires Aeterna Inc. Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
ES2301197T3 (es) * 1997-05-27 2008-06-16 Sembiosys Genetics Inc. Utilizaciones de cuerpos oleosos.
AU1597199A (en) * 1997-11-25 1999-06-15 Cornell Research Foundation Inc. Methods and compositions for inhibiting hiv infectivity and blocking chemokine activity
KR20010105403A (ko) * 1999-03-31 2001-11-28 마빈 씨. 구트리 트롬보스폰딘-2 및 이의 용도
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis

Also Published As

Publication number Publication date
WO2002083088A1 (en) 2002-10-24
US6712617B2 (en) 2004-03-30
EP1377253A1 (en) 2004-01-07
TWI233361B (en) 2005-06-01
US20030008821A1 (en) 2003-01-09
KR20080108366A (ko) 2008-12-12
JP2004526758A (ja) 2004-09-02
KR20040021598A (ko) 2004-03-10
EP1377253A4 (en) 2008-09-03
CN100340287C (zh) 2007-10-03
CN1512868A (zh) 2004-07-14

Similar Documents

Publication Publication Date Title
US6712617B2 (en) Methods of preventing UVB-induced skin damage
US6773881B2 (en) Methods of modulating hair growth
McGrath et al. Structure and function of the skin
Foitzik et al. Control of murine hair follicle regression (catagen) by TGF‐β1 in vivo
ES2403517T3 (es) Aparato y método de procesamiento de datos
AU2001253012B2 (en) Methods of modulating hair growth
US20020086013A1 (en) Methods of modulating fibrosis
AU2001253012A1 (en) Methods of modulating hair growth
Hanakawa et al. Desmogleins 1 and 3 in the companion layer anchor mouse anagen hair to the follicle
ES2402672T3 (es) Uso del GDF-5 para el mejoramiento o el mantenimiento del aspecto dérmico
US20050276765A1 (en) Preventing skin damage
US20100247627A1 (en) Foxn1 and pigmentation
AU2002254588B2 (en) Methods of Preventing UVB-Induced Skin Damage
US20020048582A1 (en) Methods of modulating angiogenesis
AU2002254588A1 (en) Methods of Preventing UVB-Induced Skin Damage
US20050281761A1 (en) Methods of preventing UVB-induced skin damage
Erdle et al. 14. Wound Healing; Cutaneous Therapy; Hair

Legal Events

Date Code Title Description
FZDE Discontinued